(Update: August 2018) Novartis/Alcon will not discontinue the sale of Atropine 1% as they had previously announced. The decision came after consideration of the joint letter that was sent in May 2018 (below).
(May 2018) The Canadian Ophthalmological Society, the Canadian Psychiatric Association, and the CSPCP sent a joint letter to Novartis/Alcon, urging them to reconsider the upcoming discontinuation of Atropine.
View letter here
The CSPCP recommends that education (such as the Methadone4Pain course from Canadian Virtual Hospice) should be mandated in each province or territory as a criterion for prescribing Methadone. The CSPCP sent letters to the federal, provincial and territorial Ministers of Health and to provincial and territorial regulatory bodies.
Letter – English
Letter – French
In April 2018, the CSPCP joined the Ontario Medical Association and six other organizations to advocate for Dan’s Law – which seeks to remove the three-month waiting period for access to OHIP-funded palliative care and home care for Canadian residents who move to or return to Ontario. Ontario has now indicated that changes will be made to OHIP to allow for this. Hopefully other provinces will follow suit. Huge thanks to Dr. Darren Cargill for garnering widespread support for this bill.
Letter: Read More
Globe and Mail Article
Health Canada invited submissions regarding proposed regulations for monitoring of MAiD (viewable here: http://www.gazette.gc.ca/rp-pr/p1/2017/2017-12-16/html/reg6-eng.html)
The CSPCP submitted two strong recommendations:
1. To record the nature of the grievous and irremediable suffering
2. To measure, monitor, and reporting on the availability of alternatives such as palliative care, social services, and respite.
View the CSPCP submission here